{
  "name" : "dacemirror.sci-hub.se_journal-article_1fecb22aa0095bca45987aa31c4ba688_sun2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis",
    "authors" : [ "Wentong Sun", "Kun Ge", "Yan Jin", "Yu Han", "Haisong Zhang", "Guoqiang Zhou", "Xinjian Yang", "Dandan Liu", "Huifang Liu", "Xing-Jie Liang", "Jinchao Zhang" ],
    "emails" : [ "(Au@MSNs)", "Au@MSNs-ZOL" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Bone metastases occur at the advanced stage of breastcancer, and about 85% of them are associated withosteolytic lesions, which decrease patients’ life expectancy to only several years.1 Patients with bone metastasis have a higher mortality rate and suffer from pain and clinical complications such as fracture, spinal cord compression, and hypercalcemia, which seriously reduce the quality of life.2 Currently, there are two primary strategies to treat bone metastasis: inhibiting cancer cell growth and inhibiting the activity of osteoclasts. Chemotherapy is the main approach to inhibiting cancer cell growth, and efficient drug delivery to the bone metastasis is essential for success.3 However, the skeleton has a poorer blood supply than other tissues, which not only reduces the efficiency of drug delivery to bone but also leads to severe side effects caused by the lack of tissue specificity.4 Bonetargeted antiresorptive drugs are important for inhibiting the\nactivity of osteoclasts, but they have negligible effects on cancer cells. Therefore, it could be beneficial to develop a bone-targeted drug delivery system to simultaneously inhibit cancer cell proliferation and osteoclast activity.\nSome targeted agents have already been developed to enhance antiresorptive therapy, such as antibody agents and bisphosphonates.1,3 Bisphosphonates, a kind of small molecular drug, are widely used in the treatment of cancer bone metastasis and osteoporosis in postmenopausal women because of their bone-targeting ability and stability.1,3 Zoledronic acid (ZOL), a third-generation bisphosphonate, has been reported to inhibit\nReceived: January 5, 2019 Accepted: June 11, 2019\n© XXXX American Chemical Society A DOI: 10.1021/acsnano.9b00097 ACS Nano XXXX, XXX, XXX−XXX\nD ow\nnl oa\nde d\nvi a\nG U\nIL FO\nR D\nC O\nL G\no n\nJu ly\n1 7,\n2 01\n9 at\n). Se e ht tp s: //p ub s. ac s. or g/ sh ar in gg ui de lin es f or o pt io ns o n ho w to le gi\nosteolysis and restore bone density in some bone erosion diseases.5−7 Due to its strong affinity for bone, ZOL mainly distributes to and accumulates in bone rather than other tissues,5,8 and it has been employed as a bone-targeting agent in combination with chemotherapeutics in vitro and in vivo. Chaudhari et al. fabricated ZOL-conjugated docetaxel-encapsulating PLGA-PEG nanoparticles, which had significantly enhanced cytotoxicity against MCF7 and BO2 cells and showed higher retention in bone and tumor in vivo.5 Our previous work showed that bone-targeted mesoporous silica nanoparticles (MSNs) conjugated with ZOL and loaded with DOX had enhanced cytotoxicity and decreased the migration of A549 cells.9 Recently Qiao et al. developed ZOL-conjugated Gddoped mesoporous silica-coated upconversion nanoparticles loaded with plumbagin and poly(acrylic acid) , which can target bone and attenuate tumorigenesis and osteoclastogenesis in breast cancer bone metastasis.10 Their work further demonstrated that ZOL localized at the sites with high osteoclast activity in priority and targeted to bone metastasis sites. Moreover, high doses of ZOL (ZOL loading capacity >10 wt\n% in nanoparticles) had antitumor activity in vitro and in vivo.11 Therefore, based on the bone-targeting ability and antitumor acitivity of ZOL, translating high doses of ZOL to bone may provide a promising therapeutic treatment for breast cancer bone metastases.\nMSNs, with their large specific surface area, good biocompatibility, and easily functionalized surface, have been employed as drug-delivery systems for several years.12−15 In our previous work, we created a ZOL-conjugated MSN nanodelivery system with high ZOL loading capacity (about 166.8 mg/g).9 The overall growth inhibition rate of cancer cells was nearly 50% after treatment with MSNs-ZOL nanoparticles. To further inhibit cancer cell growth, while also decreasing the toxicity to normal cells, we decided to add a photothermal agent to our system. Photothermal therapy (PTT) is an effective method to ablate diverse cancers, even bone cancers, under a near-infrared (NIR) laser.16−18 Moreover, hyperthermia has been reported to increase the sensitivity to anticancer drugs and promote the efficiency of chemotherapy.19,20 In this work, we constructed a bone-targeted nanoplatform with gold nanorods enclosed inside\nFigure 1. Characterization of Au@MSNs and Au@MSNs-ZOL. (A) TEM images and (B) N2 adsorption−desorption isotherms and pore size distribution curves (inset) of Au@MSNs. (C) UV−vis spectrum of the Au@MSNs at 808 nm. (D) FTIR spectra of the Au@MSNs, free ZOL, and Au@MSNs-ZOL. (E) TG analysis curves of Au@MSNs and Au@MSNs-ZOL under a flow of air. (F) Temperature increase of an aqueous dispersion of Au@MSNs-ZOL (concentration at 0.2 mg/mL) following laser irradiation at different powers for 10 min. Thermographic images of water (G) and an aqueous dispersion of Au@MSNs-ZOL (H) at different time points under laser irradiation (808 nm) at 1.2 W/cm2. (I) ZOL release profiles for Au@MSNs-ZOL at pH 7.4 at 37 and 42 ° C. Scale bar is 50 nm.\nACS Nano Article\nDOI: 10.1021/acsnano.9b00097 ACS Nano XXXX, XXX, XXX−XXX B"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 0,
    "abstractText" : "Bone metastasis, a clinical complication of patients with advanced breast cancer, seriously reduces the quality of life. To avoid destruction of the bone matrix, current treatments focus on inhibiting the cancer cell growth and the osteoclast activity through combination therapy. Therefore, it could be beneficial to develop a bone-targeted drug delivery system to treat bone metastasis. Here, a bone-targeted nanoplatform was developed using gold nanorods enclosed inside mesoporous silica nanoparticles (Au@MSNs) which were then conjugated with zoledronic acid (ZOL). The nanoparticles (Au@ MSNs-ZOL) not only showed bone-targeting ability in vivo but also inhibited the formation of osteoclast-like cells and promoted osteoblast differentiation in vitro. The combination of Au@MSNs-ZOL and photothermal therapy (PTT), triggered by near-infrared irradiation, inhibited tumor growth both in vitro and in vivo and relieved pain and bone resorption in vivo by inducing apoptosis in cancer cells and improving the bone microenvironment. This single nanoplatform combines ZOL and PTT to provide an exciting strategy for treating breast cancer bone metastasis.",
    "creator" : "Adobe Illustrator(R) 15.0"
  }
}